Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 64196
1. Sbiti M, Bouhamidi B, Louzi L: [Proteus mirabilis septic arthritis]. Pan Afr Med J; 2017;26:197
MedlinePlus Health Information. consumer health - Infectious Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Proteus mirabilis septic arthritis].
  • [Transliterated title] Arthrite septique à Proteus mirabilis.
  • Acute septic arthritis is rare.
  • We report the case of a 61-year old patient with spontaneous Proteus mirabilis septic arthritis.
  • Patient's evolution was favorable thanks to early diagnosis and initiation of adequate antibiotic therapy.
  • Proteus mirabilis septic arthritis is rare.
  • On that basis we conducted a literature review of cases of Proteus mirabilis pyogenic arthritis to highlight the risk factors, pathogenesis, treatment and evolution of these diseases.
  • Diagnosis is commonly based on microbiological analysis, early articular puncture biopsy is performed before the initiation of antibiotic treatment, direct examination, culture and antibiogram which are useful as guidance for antibiotic therapy.
  • Septic arthritis is a diagnostic and therapeutic emergency; early management of this disease allows total healing without after-effects.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Arthritis, Infectious / diagnosis. Proteus Infections / diagnosis. Proteus mirabilis / isolation & purification
  • [MeSH-minor] Acute Disease. Humans. Male. Middle Aged. Prognosis. Risk Factors. Synovial Fluid / microbiology

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Afr J Med Med Sci. 1996 Mar;25(1):7-12 [9110049.001]
  • [Cites] Rev Rhum Engl Ed. 1996 Feb;63(2):103-10 [8689280.001]
  • [Cites] Arthritis Rheum. 1995 Dec;38(12):1819-25 [8849354.001]
  • [Cites] Pediatr Radiol. 1984;14 (5):318-22 [6472917.001]
  • [Cites] Arthritis Rheum. 1980 Aug;23(8):889-97 [6773530.001]
  • [Cites] Handchir Mikrochir Plast Chir. 2007 Apr;39(2):112-7 [17497607.001]
  • [Cites] J Med Assoc Thai. 1990 Nov;73(11):615-23 [2283490.001]
  • [Cites] Clin Microbiol Infect. 2006 Apr;12(4):309-14 [16524406.001]
  • [Cites] Ann Rheum Dis. 1986 Jun;45(6):458-63 [3729573.001]
  • [Cites] Ann Thorac Surg. 2002 Feb;73(2):427-31 [11845854.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2006 Dec;92(8 Suppl):4S46-54 [17245253.001]
  • [Cites] Clin Med (Lond). 2005 Jul-Aug;5(4):420-1 [16138503.001]
  • [Cites] Clin Microbiol Rev. 2002 Oct;15(4):527-44 [12364368.001]
  • [Cites] Isr Med Assoc J. 2001 Jan;3(1):75-6 [11344817.001]
  • [Cites] Ann Rheum Dis. 1999 Apr;58(4):214-9 [10364899.001]
  • [Cites] South Med J. 1990 May;83(5):589-91 [2188375.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2011 Jun;25(3):407-21 [22100289.001]
  • [Cites] Ann Rheum Dis. 1986 Jun;45(6):454-7 [3524479.001]
  • [Cites] Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S783-8 [2934786.001]
  • (PMID = 28674590.001).
  • [ISSN] 1937-8688
  • [Journal-full-title] The Pan African medical journal
  • [ISO-abbreviation] Pan Afr Med J
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Uganda
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Keywords] NOTNLM ; Proteus mirabilis / Septic arthritis / risk factors
  •  go-up   go-down


2. Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M: Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Manag Care Spec Pharm; 2017 Aug;23(8):859-867
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
  • The impact of these services on patient adherence to adalimumab and direct medical costs associated with autoimmune disease has not been assessed.
  • The sample included patients aged ≥ 18 years with a diagnosis of Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis who were biologic-naïve before initiation of adalimumab.
  • Patients who enrolled in the PSP (PSP cohort) were matched to those who did not enroll (non-PSP cohort) based on age, sex, year of treatment initiation, comorbidities, diagnosis, and initiation at a specialty pharmacy.
  • Medical costs for emergency department, inpatient, physician, and outpatient visits (all-cause and disease-related) and total costs (medical plus drug costs) were compared at 12 months following the index date using t-tests.
  • Disease-related medical costs were 22% lower for PSP than for non-PSP patients ($8,001 vs. $10,202; P = 0.045).
  • CONCLUSIONS: Patient enrollment in the PSP was associated with greater adherence, improved persistence, and reduced medical (all-cause and disease-related) and total health care costs for patients receiving adalimumab therapy.
  • Impact of AbbVie's patient support program on resource costs in Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis.
  • 2015;21(Suppl 4a):S74-75 (poster presentation at Academy of Managed Care, 27th Annual Meeting and Expo; April 7-10, 2015; San Diego, CA) and as abstract 2339 in Arthritis Rheumatol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28737994.001).
  • [ISSN] 2376-1032
  • [Journal-full-title] Journal of managed care & specialty pharmacy
  • [ISO-abbreviation] J Manag Care Spec Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Zhao P, Chen KL, Zhang GL, Deng GR, Li J: Pharmacological Basis for Use of <i>Selaginella moellendorffii</i> in Gouty Arthritis: Antihyperuricemic, Anti-Inflammatory, and Xanthine Oxidase Inhibition. Evid Based Complement Alternat Med; 2017;2017:2103254

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacological Basis for Use of <i>Selaginella moellendorffii</i> in Gouty Arthritis: Antihyperuricemic, Anti-Inflammatory, and Xanthine Oxidase Inhibition.
  • This study was aimed at evaluating the effects of <i>Selaginella moellendorffii</i> Hieron. (SM) on gouty arthritis and getting an insight of the possible mechanisms.
  • The paw oedema, the neutrophil accumulation, inflammatory mediators, lipid peroxidation, and histopathological changes of the joints were analyzed in gouty arthritis rat model, and the kidney injury and serum urate were detected in hyperuricemic mice.
  • The high dose of SM extract could significantly prevent the paw swelling, reduce gouty joint inflammatory features, reduce the release of IL-1<i>β</i> and TNF-<i>α</i>, lower malondialdehyde (MDA) and myeloperoxidase (MPO) levels, and increase superoxide dismutase (SOD) level (<i>P</i> < 0.01).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1093-103 [15014182.001]
  • [Cites] Pain. 1987 Mar;28(3):379-93 [3574965.001]
  • [Cites] Immunol Rev. 2010 Jan;233(1):218-32 [20193002.001]
  • [Cites] Inflammation. 2011 Jun;34(3):184-92 [20495860.001]
  • [Cites] Nat Rev Rheumatol. 2010 Jan;6(1):30-8 [20046204.001]
  • [Cites] Zhongguo Zhong Yao Za Zhi. 2005 Oct;30(19):1507-10 [16335819.001]
  • [Cites] Anticancer Agents Med Chem. 2015;15(6):728-35 [25738871.001]
  • [Cites] Fitoterapia. 2010 Jun;81(4):253-8 [19775597.001]
  • [Cites] J Nutr. 2009 Jun;139(6):1095-102 [19403720.001]
  • [Cites] Fitoterapia. 2007 Dec;78(7-8):598-9 [17582697.001]
  • [Cites] J Clin Invest. 1993 Oct;92(4):1722-9 [7691884.001]
  • [Cites] N Engl J Med. 2011 Feb 3;364(5):443-52 [21288096.001]
  • [Cites] Free Radic Biol Med. 2009 Sep 1;47(5):616-21 [19500663.001]
  • [Cites] Crit Rev Food Sci Nutr. 2015 Jul 15;:0 [26176651.001]
  • [Cites] Arthritis Rheum. 2004 Aug;50(8):2400-14 [15334451.001]
  • [Cites] Curr Opin Rheumatol. 2007 Mar;19(2):146-50 [17278929.001]
  • [Cites] Planta Med. 1999 Jun;65(5):465-7 [10418340.001]
  • [Cites] J Leukoc Biol. 2001 Oct;70(4):659-68 [11590204.001]
  • [Cites] Int J Nephrol Renovasc Dis. 2010;3:145-66 [21694941.001]
  • [Cites] Ann Rheum Dis. 2012 Nov;71(11):1765-70 [22863577.001]
  • [Cites] Arthritis Res Ther. 2006;8 Suppl 1:S3 [16820042.001]
  • [Cites] Nat Rev Rheumatol. 2014 May;10(5):271-83 [24614592.001]
  • [Cites] BMC Complement Altern Med. 2015 Apr 25;15:131 [25906842.001]
  • [Cites] Phytomedicine. 2011 May 15;18(7):561-6 [21144719.001]
  • [Cites] J Mol Evol. 1992 Jan;34(1):78-84 [1556746.001]
  • [Cites] J Leukoc Biol. 1997 Oct;62(4):444-9 [9335313.001]
  • [Cites] Food Chem Toxicol. 2010 Jan;48(1):229-35 [19819286.001]
  • [Cites] Arthritis Res Ther. 2011;13(5):R164 [21992185.001]
  • [Cites] J Nat Prod. 1998 Jan;61(1):71-6 [9461655.001]
  • (PMID = 28250791.001).
  • [ISSN] 1741-427X
  • [Journal-full-title] Evidence-based complementary and alternative medicine : eCAM
  • [ISO-abbreviation] Evid Based Complement Alternat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Tanwar A, Chawla R, Ansari MM, Neha, Thakur P, Chakotiya AS, Goel R, Ojha H, Asif M, Basu M, Arora R, Khan HA: In vivo anti-arthritic efficacy of Camellia sinensis (L.) in collagen induced arthritis model. Biomed Pharmacother; 2017 Mar;87:92-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo anti-arthritic efficacy of Camellia sinensis (L.) in collagen induced arthritis model.
  • BACKGROUND: Rheumatoid arthritis (RA), an autoimmune inflammatory disorder with synovial hyperplasia, destruction of cartilage, bone damage is often associated with risk of infections.
  • Four different oral doses (50, 100, 200, 400mg/kg/body wt.) of aquo-alcoholic extract were evaluated for anti-edematogenic effect in collagen induced arthritis model.
  • The selected anti-arthritic doses of Cs were evaluated for the oxidative stress markers like Glutathione [5-5'dithio-bis-2-nitrobenzoicacid (DTNB)], Superoxide dismutase [Epinephrine], Catalase [Hydrogen peroxide], Lipid peroxidation [Thiobarbituric acid reactive substance (TBARS)], Nitric oxide [Griess reagents:Nitrobluetetrazolium], Articular elastase [N-methoxysuccinyl-Ala-Ala-Pro- Val p-nitroanilide] in joints followed by haematological evaluation including RBC, WBC, Haemoglobin, platelets and haematocrit.
  • The confirmatory analysis utilizing radiological and histological assessment showed alleviation of joint deformity, tissue swelling, pannus formation and neutrophils infiltration in treatment group as compared to collagen induced arthritis.
  • CONCLUSION: The analysis showed that Cs can play an effective role in reduction of oxidative stress by modulating levels of antioxidants, reducing levels of free radicals while restoring normal haematopoietic cascade as observed in collagen induced arthritis model.
  • Thus, the cumulative dose impact of 400mg/kg body wt., over a period of 14days also found extremely effective in terms of safeguarding their structural conformity against such auto-immune disorder.
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Arthritis, Experimental / drug therapy. Arthritis, Experimental / pathology. Camellia sinensis. Plant Extracts / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier Masson SAS. All rights reserved.
  • (PMID = 28049097.001).
  • [ISSN] 1950-6007
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Plant Extracts
  • [Keywords] NOTNLM ; Anti-inflammatory / Aquo alcoholic extract / Camellia sinensis / Collagen induced arthritis / Oxidative stress
  •  go-up   go-down


5. Ruscitti P, Cipriani P, Masedu F, Romano S, Berardicurti O, Liakouli V, Carubbi F, Di Benedetto P, Alvaro S, Penco M, Valenti M, Giacomelli R: Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. PLoS One; 2017;12(1):e0170108
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study.
  • OBJECTIVES: Several studies showed the close relationship between Rheumatoid Arthritis (RA) and cerebro-cardiovascular events (CVEs) and subclinical atherosclerosis.
  • In this study, we investigated the occurrence of CVEs and subclinical atherosclerosis during the course of RA and we evaluated the possible role of both traditional cardiovascular (CV) and disease related risk factors to predict the occurrence of new CVEs and the onset of subclinical atherosclerosis.
  • Statistical analyses were performed to evaluate the role of traditional CV and disease-related risk factors to predict the occurrence of new CVEs and subclinical atherosclerosis.
  • The occurrence of both new CVEs and subclinical atherosclerosis in RA patients may be explained by inflammatory burden as well as traditional CV risk factors.
  • [MeSH-major] Arthritis, Rheumatoid / complications. Atherosclerosis / etiology. Cardiovascular Diseases / etiology

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rheumatology (Oxford). 2014 Dec;53(12):2143-54 [24907149.001]
  • [Cites] Ann Rheum Dis. 2013 Apr;72(4):560-5 [22589377.001]
  • [Cites] Ann Rheum Dis. 2010 Feb;69(2):325-31 [19773290.001]
  • [Cites] Rheumatology (Oxford). 2008 Sep;47(9):1286-98 [18467370.001]
  • [Cites] Rheumatology (Oxford). 2008 Jan;47(1):72-5 [18077493.001]
  • [Cites] PLoS One. 2013 Oct 25;8(10):e78151 [24205134.001]
  • [Cites] PLoS One. 2015 Feb 17;10(2):e0117952 [25689371.001]
  • [Cites] Nat Rev Rheumatol. 2015 Dec;11(12):693-704 [26282082.001]
  • [Cites] Autoimmun Rev. 2015 Oct;14(10):952-69 [26117596.001]
  • [Cites] Joint Bone Spine. 2016 Mar;83(2):127-33 [26184539.001]
  • [Cites] Am J Epidemiol. 1999 Jun 1;149(11):981-3 [10355372.001]
  • [Cites] Nat Rev Rheumatol. 2014 Jul;10(7):403-12 [24686510.001]
  • [Cites] Autoimmun Rev. 2013 Aug;12(10):1004-15 [23541482.001]
  • [Cites] Circulation. 2003 Mar 11;107(9):1303-7 [12628952.001]
  • [Cites] Arthritis Rheum. 2010 Sep;62(9):2569-81 [20872595.001]
  • [Cites] PLoS One. 2016 Jun 16;11(6):e0157360 [27310259.001]
  • [Cites] Ann Rheum Dis. 2008 Jan;67(1):64-9 [17517756.001]
  • [Cites] Ann Rheum Dis. 2004 Nov;63 Suppl 2:ii32-ii39 [15479869.001]
  • [Cites] Joint Bone Spine. 2014 Jul;81(4):298-302 [24880190.001]
  • [Cites] PLoS One. 2016 Jan 12;11(1):e0146991 [26757209.001]
  • [Cites] Rheumatology (Oxford). 2016 Jul;55(7):1210-6 [27009825.001]
  • [Cites] Ann Rheum Dis. 2014 Mar;73(3):492-509 [24161836.001]
  • [Cites] Ann Rheum Dis. 2016 Jan;75(1):3-15 [25969430.001]
  • [Cites] Circ Res. 2015 Mar 13;116(6):1022-33 [25767287.001]
  • [Cites] Arthritis Rheum. 1988 Mar;31(3):315-24 [3358796.001]
  • [Cites] Arthritis Rheum. 2008 Dec 15;59(12):1690-7 [19035419.001]
  • [Cites] Ann Rheum Dis. 2012 Sep;71(9):1524-9 [22425941.001]
  • [Cites] Lancet. 2004 Sep 11-17;364(9438):937-52 [15364185.001]
  • [Cites] Rheumatology (Oxford). 2011 Mar;50(3):450-62 [20959355.001]
  • [Cites] Thromb Haemost. 2015 May;113(5):916-30 [25716931.001]
  • [Cites] Arthritis Rheum. 2012 Jun;64(6):1828-37 [22231638.001]
  • [Cites] Arthritis Rheum. 1996 Jan;39(1):34-40 [8546736.001]
  • [Cites] Ann Rheum Dis. 2015 Jun;74(6):998-1003 [24458537.001]
  • [Cites] Expert Rev Clin Immunol. 2016 Aug;12(8):849-55 [26999417.001]
  • [Cites] Ann Rheum Dis. 2010 Sep;69(9):1660-4 [20498206.001]
  • [Cites] Arthritis Rheumatol. 2014 Feb;66(2):264-72 [24504798.001]
  • [Cites] Arthritis Rheumatol. 2015 Jun;67(6):1449-55 [25776112.001]
  • [Cites] N Engl J Med. 2011 Dec 8;365(23):2205-19 [22150039.001]
  • [Cites] Arthritis Res Ther. 2011 Aug 15;13(4):R131 [21843325.001]
  • [Cites] Cerebrovasc Dis. 2007;23 (1):75-80 [17108679.001]
  • [Cites] J Rheumatol. 2006 Dec;33(12 ):2425-32 [17080519.001]
  • (PMID = 28103312.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Observational Study
  • [Publication-country] United States
  •  go-up   go-down


6. Yuan Y, Yang H, Kong L, Li Y, Li P, Zhang H, Ruan J: Interaction between rhein acyl glucuronide and methotrexate based on human organic anion transporters. Chem Biol Interact; 2017 Sep 07;277:79-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rhein, a major bioactive compound of many medicinal herbs and the prodrug of diacerein, is often used with low dose of methotrexate as drug combination to treat rheumatoid arthritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28890383.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Keywords] NOTNLM ; Drug-drug interaction / Methotrexate / Organic anion transporter / Rhein / Rhein acyl glucuronide
  •  go-up   go-down


7. Havens E, Slabaugh SL, Helmick CG, Cordier T, Zack M, Gopal V, Prewitt T: Comorbid Arthritis Is Associated With Lower Health-Related Quality of Life in Older Adults With Other Chronic Conditions, United States, 2013-2014. Prev Chronic Dis; 2017 Jul 27;14:E60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbid Arthritis Is Associated With Lower Health-Related Quality of Life in Older Adults With Other Chronic Conditions, United States, 2013-2014.
  • INTRODUCTION: Arthritis is related to poor health-related quality of life (HRQoL) in adults aged 18 years or older.
  • We sought to determine whether this relationship persisted in an older population using claims-based arthritis diagnoses and whether people who also had arthritis and at least 1 of 5 other chronic conditions had lower HRQoL.
  • For respondents with and without arthritis, we used linear regression to compare mean physically, mentally, and total unhealthy days, overall and in 5 comorbidity subgroups (coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, diabetes, and hypertension), accounting for age, sex, dual Medicaid/Medicare eligibility, rural/urban commuting area, and Charlson Comorbidity Index.
  • RESULTS: Of the 58,975 survey respondents, 44% had arthritis diagnosed through claims.
  • Respondents with arthritis reported significantly more adjusted mean physically, mentally, and total unhealthy days than those without arthritis (P < .001).
  • Older adults with arthritis and either congestive heart failure, chronic obstructive pulmonary disease, diabetes, or hypertension reported significantly more adjusted physically, mentally, and total unhealthy days than older adults without arthritis but with the same chronic conditions.
  • CONCLUSIONS: In older adults, having arthritis is associated with lower HRQoL and even lower HRQoL among those with at least 1 of 5 other common chronic conditions.
  • Because arthritis is so common among older adults, improving HRQoL depends on managing both underlying chronic conditions and any accompanying arthritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aging Clin Exp Res. 2002 Dec;14(6):499-508 [12674491.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 2013 Jan;68(1):107-16 [23197340.001]
  • [Cites] Arthritis. 2014;2014:256498 [25152816.001]
  • [Cites] Health Qual Life Outcomes. 2004 Jan 13;2:5 [14720300.001]
  • [Cites] Qual Life Res. 2013 Jun;22(5):987-95 [22797867.001]
  • [Cites] J Epidemiol Community Health. 2004 Feb;58(2):150-5 [14729899.001]
  • [Cites] Health Technol Assess. 2006 Nov;10 (42):iii-iv, xi-xiii, 1-229 [17049139.001]
  • [Cites] Arthritis Care Res (Hoboken). 2011 Jun;63(6):788-99 [21538946.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2010 Oct 8;59(39):1261-5 [20930703.001]
  • [Cites] Arthritis Care Res (Hoboken). 2013 Jul;65(7):1059-69 [23401463.001]
  • [Cites] Qual Life Res. 2012 Oct;21(8):1347-57 [22038394.001]
  • [Cites] Popul Health Manag. 2017 Feb;20(1):13-22 [27031869.001]
  • [Cites] J Rheumatol. 2003 Jan;30(1):160-6 [12508407.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2008 May 9;57(18):486-9 [18463606.001]
  • [Cites] Am J Public Health. 2000 Aug;90(8):1297-9 [10937013.001]
  • [Cites] Arthritis Care Res (Hoboken). 2011 May;63(5):643-53 [21225675.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):578-82 [26042649.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2011 May 20;60(19):614-8 [21597454.001]
  • [Cites] J Clin Epidemiol. 1996 Dec;49(12):1429-33 [8991959.001]
  • [Cites] Qual Life Res. 2008 May;17(4):521-8 [18365766.001]
  • [Cites] J Epidemiol Community Health. 2005 May;59(5):380-5 [15831686.001]
  • (PMID = 28749776.001).
  • [ISSN] 1545-1151
  • [Journal-full-title] Preventing chronic disease
  • [ISO-abbreviation] Prev Chronic Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Wang X, Zu Y, Huang L, Yu J, Zhao H, Wen C, Chen Z, Xu Z: Treatment of rheumatoid arthritis with combination of methotrexate and Tripterygium wilfordii: A meta-analysis. Life Sci; 2017 Feb 15;171:45-50
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of rheumatoid arthritis with combination of methotrexate and Tripterygium wilfordii: A meta-analysis.
  • AIMS: Extracts of Tripterygium wilfordii Hook F (TwHF), a traditional Chinese herbal medicine, have been widely used for treating rheumatoid arthritis (RA) in combination with methotrexate (MTX) in China for several decades.
  • For efficacy, the addition of TwHF increased 50% responder rates (RR) (RR 1.337, 95% confidence interval [CI]: 1.188-1.505, P<0.001), and it reduced swollen and tender joint counts, shortened the duration of morning stiffness, decreased the erythrocyte sedimentation rate, and decreased the level of C-reactive protein and rheumatoid factor.
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Arthritis, Rheumatoid / drug therapy. Methotrexate / therapeutic use. Plant Extracts / therapeutic use. Tripterygium / chemistry

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28088452.001).
  • [ISSN] 1879-0631
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Plant Extracts; YL5FZ2Y5U1 / Methotrexate
  • [Keywords] NOTNLM ; Meta-analysis (major topic) / Methotrexate (major topic) / Rheumatoid arthritis (major topic) / Tripterygium wilfordii (major topic)
  •  go-up   go-down


9. Der Ananian C, Smith-Ray R, Meacham B, Shah A, Hughes S: Translation of Fit & Strong! for Use by Hispanics With Arthritis: A Feasibility Trial of ¡En Forma y Fuerte! J Aging Phys Act; 2017 Sep 22;:1-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translation of Fit & Strong! for Use by Hispanics With Arthritis: A Feasibility Trial of ¡En Forma y Fuerte!
  • on arthritis-related outcomes in Hispanics with arthritis.
  • is feasible and effective, potentially providing a much-needed program for older Hispanics with arthritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28290760.001).
  • [ISSN] 1543-267X
  • [Journal-full-title] Journal of aging and physical activity
  • [ISO-abbreviation] J Aging Phys Act
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; aging / arthritis / exercise / physical activity / physical function
  •  go-up   go-down


10. Polachek A, Li S, Polachek IS, Chandran V, Gladman D: Psoriatic arthritis disease activity during pregnancy and the first-year postpartum. Semin Arthritis Rheum; 2017 Jun;46(6):740-745
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psoriatic arthritis disease activity during pregnancy and the first-year postpartum.
  • OBJECTIVES: To evaluate disease activity in the joints and skin during pregnancy and the first-year postpartum in patients with psoriatic arthritis (PsA).
  • The course of joint and skin disease activity was defined by the following 5 states: improvement, worsening, stable low, stable high, or a mixed.
  • Arthritis improved or was stable low activity in 24 (58.5%) of pregnancies.
  • During the postpartum period, 21 (52.5%) had either improvement or stable low PsA activity, whereas 16 (40%) had either worsening or stable high disease activity.
  • A logistic regression analysis revealed a favourable skin disease course during the pregnancy period in the pregnant group compared to the control group (OR = 6.8, p = 0.004), but not in joint disease.
  • Arthritis activity trends toward a favourable course while the skin disease shows a favorable course during pregnancy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28196621.001).
  • [ISSN] 1532-866X
  • [Journal-full-title] Seminars in arthritis and rheumatism
  • [ISO-abbreviation] Semin. Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Birth / Gestation / Joints / Psoriatic arthritis / Skin / Treatment
  •  go-up   go-down






Advertisement